Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Centessa Pharmaceuticals Plc ADR (NQ: CNTA ) 8.580 -0.190 (-2.17%) Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 110,226 Open 8.800 Bid (Size) 3.450 (2) Ask (Size) 8.660 (2) Prev. Close 8.770 Today's Range 8.500 - 8.810 52wk Range 5.150 - 12.45 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer June 10, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences May 21, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Performance YTD +6.85% +6.85% 1 Month +0.94% +0.94% 3 Month -24.27% -24.27% 6 Month +6.85% +6.85% 1 Year +41.82% +41.82% More News Read More CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024 May 13, 2024 Via InvestorPlace Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 May 13, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares April 23, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 April 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 March 28, 2024 Via InvestorPlace Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 March 28, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire 7 Biotech Stocks Ready to Ride the Sector’s Resurgence March 18, 2024 Via InvestorPlace Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference February 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session February 09, 2024 Via Benzinga SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday February 09, 2024 Via Benzinga Topics Stocks Exposures US Equities Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and February 09, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences January 22, 2024 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference December 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia December 10, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session November 27, 2023 Via Benzinga Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals November 27, 2023 From AnaptysBio, Inc. Via GlobeNewswire Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 November 13, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting November 02, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors October 31, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences October 30, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday October 26, 2023 Via Benzinga Topics Stocks Exposures US Equities Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders October 25, 2023 From Centessa Pharmaceuticals plc Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
